Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Adcetris' Phase III Hodgkin's readout leaves investors wanting

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Adcetris brentuximab vedotin met the primary endpoint in the Phase III ECHELON-1 study as a first-line therapy for classical Hodgkin's lymphoma (cHL). Despite the trial's overall outcome, investors appeared unimpressed

Read the full 410 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE